BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy
Go back to BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy| (NYSE: PHGE) | Delayed: 0.35 +0.05 (16.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.30 | 52 Week High | $ | |||
| Open | $0.33 | 52 Week Low | $ | |||
| Day High | $0.35 | P/E | N/A | |||
| Day Low | $0.30 | EPS | $ | |||
| Volume | 220,395 | |||||
